Zivo Bioscience, Inc. Annual Meeting of Shareholders Web Link Instructions

0

KEEGO HARBOR, Michigan, October 05, 2021 (GLOBE NEWSWIRE) – Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech / agtech R&D company engaged in the development and marketing of therapeutic, medicinal and nutritional product candidates originating from exclusive algae cultures, is today publishing a notice to its shareholders concerning the annual meeting of shareholders.

In accordance with the Notice previously provided for the Annual Meeting of Shareholders of Zivo Bioscience, Inc., (“Zivo” or the “Company”) to be held on Tuesday, October 12, 2021 at 9 a.m. EST., the web link for virtual participation is provided below.

Web link: https://agm.issuerdirect.com/zivo

Control ID for the shareholderA: For shareholder control IDs, shareholders should refer to their proxy card received for their control ID.

Control ID for other participants: 00000000 (* nine zeros)

(Note: For public health concerns regarding the Coronavirus (COVID-19), the Annual Meeting will be held in a virtual format as well as in person at 3600 Centerpoint Parkway, Pontiac, MI 48341.)

The proxy statement as filed is available at:

About Zivo Bioscience, Inc.

Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a Michigan-based biotechnology / agtech company investigating the health and nutritional benefits of bioactive compounds derived from its proprietary algae cultures, and the development of naturally occurring bioactive compounds at use as a dietetic. food supplements and ingredients, as well as synthetic and biologically derived candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on the general benefits of modulating the autoimmune and inflammatory response. Visit zivobioscience.com to learn more.

Forward-looking statements

Except for all historical information, the matters discussed in this document contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that such statements are based on a combination of facts and factors currently known to us and our expectations for the future, of which we cannot be certain. Our actual future results may differ materially from what we expect due to factors largely beyond our control, including the risks that our strategic partnerships will not facilitate the commercialization or market acceptance of our products; the risks that our products may not be ready for market on a timely basis or not at all; the risks that our products will not perform as expected based on the results of our preclinical and clinical trials; our ability to raise additional funds; the uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; clinical trial results, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under “Risk Factors” in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and ZIVO assumes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

Contacts:

Investor Relations
BASIC IR
516-222-2560
[email protected]

Media
BASIC IR
Jules Abraham
917-885-7378
[email protected]

Source: Zivo Bioscience, Inc.


Source link

Leave A Reply

Your email address will not be published.